Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Status:
Completed
Trial end date:
2021-03-26
Target enrollment:
Participant gender:
Summary
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3
receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy
induced nausea or vomiting (CINV). Subjects receive a single dose of palonosetron prior to
moderately emetogenic chemotherapy.